Latest Pharma and Biotech News
Biotechnology
7 November 2024 According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either.
Today's issue
Refine Search
Pharmaceutical
Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data for its investigational medicine VK2738 at the ObesityWeek meeting. US biotech Beam Therapeutics released early-stage data on its sickle cell disease candidate BEAM-101. Also of note, Arcus Biosciences and Gilead Sciences announced promising Phase III results for their TIGIT inhibitor domvanalimab in combination with zimberelimab. Denmark’s Novo Nordisk released financial results that attracted interest. 10 November 2024
Biotechnology
New research has been published in the Journal of Allergy and Clinical Immunology (JACI) that shows treatment with amlitelimab, an anti-OX40 ligand antibody, significantly reduced symptoms of atopic dermatitis (AD) and was maintained even after treatment stopped. 9 November 2024
Biotechnology
South Korea’s Alteogen has signed an exclusive licensing agreement with Japanese pharmaceutical company Daiichi Sankyo for its human hyaluronidase, ALT-B4. 9 November 2024
Pharmaceutical
Shanghai-based Dizal has made a submission to the US Food and Drug Administration, seeking approval for sunvozertinib. 8 November 2024
Pharmaceutical
Viracta Therapeutics has announced a significant restructuring to prioritize its lead oncology candidate, nana-val (valganciclovir/valganciclovir sodium), aimed at treating certain people with peripheral T-cell lymphoma (PTCL). 8 November 2024
Pharmaceutical
Pfizer has announced plans to invest $1 billion in China by 2030, targeting accelerated innovation, diagnostics improvements, and support for the local biotechnology sector. 8 November 2024
Biotechnology
AlloVir has entered into a definitive agreement to merge with biopharma company Kalaris Therapeutics. 8 November 2024
Biotechnology
US mRNA specialist Moderna today announced Health Canada has approved mRESVIA (respiratory syncytial virus mRNA vaccine) for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults 60 years of age and older. 8 November 2024
Biotechnology
US healthcare giant Johnson & Johnson today revealed it has submitted applications with the US Food and drug Administration (FDA) and European Medicines Agency (EMA) to expand the approved indications for its Darzalex (daratumumab) subcutaneous (SC) formulation for the treatment of high-risk smouldering multiple myeloma (SMM). 8 November 2024
Pharmaceutical
A review has found that complexities and inefficiencies within the UK’s health data infrastructure are hindering the effective use of these resources that are critical for improving people’s health. 8 November 2024
Pharmaceutical
Italian pharma major Recordati saw its shares dip 3.75% to 50.10 euros this morning, despite posting a set of strong financial results. 8 November 2024
Biotechnology
Genmab announced during its third-quarter earnings call on Wednesday that it has discontinued three antibody programs as part of a pipeline overhaul. 8 November 2024
Biotechnology
Japanese ophthalmology company Santen Pharmaceutical has crossed the East China Sea in its latest collaboration, announced on Thursday. 8 November 2024
Biotechnology
US biotech major Amgen and the UK’s AstraZeneca have announced positive top-line results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]). 8 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Generics
US generic drugmaker Viatris announced robust financial results for the third quarter of 2024, driven by positive momentum against all three pillars of its strategy. The company’s shares shot up 13.5% to $13.18 following the announcement. 8 November 2024
Pharmaceutical
Following the news that Donald Trump is the winner of the 2024 US Presidential Election, Morningstar Equity analyst Julie Utterback has published a new note about the impact of this on the managed-care industry. 7 November 2024
Pharmaceutical
Jazz Pharmaceuticals has reported third-quarter revenue of $1 billion, a 9% increase over the prior year, fueled by strong performance in its key sleep and epilepsy portfolios. 7 November 2024
Biotechnology
Asklepios BioPharmaceutical (AskBio) today announced that AB-1003 (also known as LION-101) has received rare pediatric disease designation and orphan-drug designation from the US Food and Drug Administration (FDA) for the treatment of limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). 7 November 2024
Biotechnology
The global market for Duchenne muscular dystrophy (DMD) therapeutics is projected to grow by $4.4 billion between 2024 and 2028, fueled by artificial intelligence and strong demand for new treatments. 7 November 2024
All news
Biotechnology
Swiss biotech Basilea Pharmaceutica revealed it has entered into an asset purchase agreement with the Glioblastoma Foundation for its oncology drug candidate lisavanbulin (BAL101553), which has been developed as a potential therapy for glioblastoma, the most common type of primary brain cancer. 21 June 2024
Biotechnology
Johnson & Johnson has submitted for an additional approval for Tremfya (guselkumab) to treat adults with moderately to severely active Crohn's disease. 21 June 2024
Biotechnology
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has approved Crysvita (burosumab) from Japanese drugmaker Kyowa Kirin. 21 June 2024
Pharmaceutical
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended Eladynos (abaloparatide). 21 June 2024
Biotechnology
California-based āshibio, a privately-held biotech developing therapeutics for bone and connective tissue disorders, has exited stealth mode today with $40 million in seed and Series A financing. 21 June 2024
Biosimilars
In the USA, the Food and Drug Administration has announced the availability of a draft guidance for industry which could smooth the path for biosimilars developers to gain interchangeable status for their products. 21 June 2024
Pharmaceutical
Audrey Duval Derveloy, currently president of Sanofi France, has been named executive vice president, global head of corporate affairs. 21 June 2024
Biotechnology
US precision genetic medicines firm Sarepta Therapeutic saw its close up 5% and soar a further 36.5% to $168.55 in after-hours activity, as it revealed a welcome indication extension for its Duchenne muscular dystrophy (DMD) drug. 21 June 2024
Pharmaceutical
Swedish autoimmune specialist Aqilion and Merck KGaA have decided to terminate their joint development of their TAK1 program. 21 June 2024
Pharmaceutical
New data analysis by University of Bath, UK, and Lund University, Sweden, academics reveals that public health in the UK could be undermined by a failing system of drug company self-regulation. 21 June 2024
Biotechnology
The US Food and Drug Administration (FDA) has announced the availability of a final guidance for industry entitled Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics, replacing the June 2022 draft guidance on this topic. 21 June 2024
Pharmaceutical
Gilead Sciences shares were up 7.6% at $67.96, as the US antivirals major released positive trial data. 20 June 2024
Pharmaceutical
French vaccines major Sanofi and Biovac, a Cape Town-based biopharmaceutical company, have announced a partnership to produce inactivated polio vaccines in Africa. 20 June 2024
Pharmaceutical
US biopharma company Vanda Pharmaceuticals on Wednesday revealed that it has rejected takeover offers from UK-based Cycle Pharmaceutical and a revised bid from contract manufacturer Future Pak, arguing that both offers undervalue the company. 20 June 2024
Biotechnology
Sanofi today revealed that UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued final draft guidance (FDG) not recommending Sarclisa (isatuximab) plus pomalidomide and dexamethasone (Isa-Pd), within its marketing authorization 20 June 2024
Pharmaceutical
Munich-based radiopharmaceutical company ITM Isotope Technologies has appointed Andrew Cavey as its new chief executive officer. 20 June 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has approved Sofdra (sofpironium) topical gel, 12.45%. 20 June 2024
Pharmaceutical
Bensheim-based medical cannabis specialist Avextra has announced a strategic partnership with fellow German firm SynQube. 20 June 2024
Pharmaceutical
Spanish plasma-derived products specialist Grifols announced it has completed the sale of a 20% equity stake in Shanghai RAAS (SRAAS) to Haier Group Corp. 20 June 2024
Biotechnology
Shanghai-based Dizal Pharmaceutical announced that the National Medical Products Administration of China has approved golidocitinib. 20 June 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze